Application number | Title of the application | Filing Date | Status |
---|
Array
(
[id] => 18436391
[patent_doc_number] => 20230183685
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => SYNTHETIC TRANSFER RNA WITH EXTENDED ANTICODON LOOP
[patent_app_type] => utility
[patent_app_number] => 17/876803
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10270
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17876803
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/876803 | Synthetic transfer RNA with extended anticodon loop | Jul 28, 2022 | Issued |
Array
(
[id] => 18212600
[patent_doc_number] => 20230058864
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIC CALCIFICATION
[patent_app_type] => utility
[patent_app_number] => 17/814968
[patent_app_country] => US
[patent_app_date] => 2022-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22358
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814968
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/814968 | Compositions and methods for treating pathologic calcification | Jul 25, 2022 | Issued |
Array
(
[id] => 18193954
[patent_doc_number] => 20230047473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => siRNA based on RNA sequence of SARS-CoV-2 and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/811961
[patent_app_country] => US
[patent_app_date] => 2022-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8160
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811961
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/811961 | siRNA based on RNA sequence of SARS-CoV-2 and use thereof | Jul 11, 2022 | Pending |
Array
(
[id] => 18910521
[patent_doc_number] => 11873492
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-16
[patent_title] => Medication and diagnostic kit for inhibiting metastasis and invasion of breast cancer, shRNA molecule for silencing expression of human LINC01614 and application thereof
[patent_app_type] => utility
[patent_app_number] => 17/852380
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 3330
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852380
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/852380 | Medication and diagnostic kit for inhibiting metastasis and invasion of breast cancer, shRNA molecule for silencing expression of human LINC01614 and application thereof | Jun 28, 2022 | Issued |
Array
(
[id] => 18058342
[patent_doc_number] => 20220389428
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING THE SAME, AND PREPARATION METHOD AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/852888
[patent_app_country] => US
[patent_app_date] => 2022-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42617
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17852888
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/852888 | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | Jun 28, 2022 | Issued |
Array
(
[id] => 18511673
[patent_doc_number] => 20230227855
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related Disorders
[patent_app_type] => utility
[patent_app_number] => 17/851227
[patent_app_country] => US
[patent_app_date] => 2022-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851227
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/851227 | Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related Disorders | Jun 27, 2022 | Pending |
Array
(
[id] => 18485247
[patent_doc_number] => 20230212580
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => INHIBITION OF POLYOMAVIRUS REPLICATION
[patent_app_type] => utility
[patent_app_number] => 17/846457
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21008
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846457 | INHIBITION OF POLYOMAVIRUS REPLICATION | Jun 21, 2022 | |
Array
(
[id] => 18854095
[patent_doc_number] => 11851658
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-26
[patent_title] => Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
[patent_app_type] => utility
[patent_app_number] => 17/836789
[patent_app_country] => US
[patent_app_date] => 2022-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 29
[patent_no_of_words] => 74030
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17836789
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/836789 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | Jun 8, 2022 | Issued |
Array
(
[id] => 18108017
[patent_doc_number] => 20230000897
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents
[patent_app_type] => utility
[patent_app_number] => 17/829801
[patent_app_country] => US
[patent_app_date] => 2022-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27485
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829801
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/829801 | Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents | May 31, 2022 | Pending |
Array
(
[id] => 19104633
[patent_doc_number] => 11957706
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Composition for preventing or treating fibrosis including an inhibitor of CDK17 expression or activity
[patent_app_type] => utility
[patent_app_number] => 17/828351
[patent_app_country] => US
[patent_app_date] => 2022-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 12
[patent_no_of_words] => 7086
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17828351
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/828351 | Composition for preventing or treating fibrosis including an inhibitor of CDK17 expression or activity | May 30, 2022 | Issued |
Array
(
[id] => 17828392
[patent_doc_number] => 20220265696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => MICRO-RNAS AND COMPOSITIONS COMPRISING SAME FOR THE TREATMENT AND DIAGNOSIS OF SEROTONIN-, ADRENALIN-, NORADRENALIN-, GLUTAMATE-, AND CORTICOTROPIN-RELEASING HORMONE- ASSOCIATED MEDICAL CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/734199
[patent_app_country] => US
[patent_app_date] => 2022-05-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34416
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/734199 | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | May 1, 2022 | Issued |
Array
(
[id] => 18452003
[patent_doc_number] => 20230193282
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => TREATMENT METHODS FOR MUSCULAR DYSTROPHY
[patent_app_type] => utility
[patent_app_number] => 17/732757
[patent_app_country] => US
[patent_app_date] => 2022-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17732757
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/732757 | TREATMENT METHODS FOR MUSCULAR DYSTROPHY | Apr 28, 2022 | Pending |
Array
(
[id] => 18311030
[patent_doc_number] => 20230114930
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => Compounds and Methods for Reducing LRRK2 Expression
[patent_app_type] => utility
[patent_app_number] => 17/712822
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17712822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/712822 | Compounds and methods for reducing LRRK2 expression | Apr 3, 2022 | Issued |
Array
(
[id] => 18294439
[patent_doc_number] => 20230104125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
[patent_app_type] => utility
[patent_app_number] => 17/709539
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709539
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/709539 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | Mar 30, 2022 | Abandoned |
Array
(
[id] => 17749944
[patent_doc_number] => 20220228149
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
[patent_app_type] => utility
[patent_app_number] => 17/709087
[patent_app_country] => US
[patent_app_date] => 2022-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/709087 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | Mar 29, 2022 | Issued |
Array
(
[id] => 19181211
[patent_doc_number] => 11987794
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-21
[patent_title] => Products and compositions
[patent_app_type] => utility
[patent_app_number] => 17/688789
[patent_app_country] => US
[patent_app_date] => 2022-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 33
[patent_no_of_words] => 26503
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 205
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17688789
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/688789 | Products and compositions | Mar 6, 2022 | Issued |
Array
(
[id] => 17836390
[patent_doc_number] => 20220273695
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => MCM FOR GENE THERAPY TO ACTIVATE WNT PATHWAY
[patent_app_type] => utility
[patent_app_number] => 17/683699
[patent_app_country] => US
[patent_app_date] => 2022-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17124
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17683699
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/683699 | MCM FOR GENE THERAPY TO ACTIVATE WNT PATHWAY | Feb 28, 2022 | Pending |
Array
(
[id] => 17897370
[patent_doc_number] => 20220307032
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/680940
[patent_app_country] => US
[patent_app_date] => 2022-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37221
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680940
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/680940 | Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) Inhibitors | Feb 24, 2022 | Pending |
Array
(
[id] => 17897421
[patent_doc_number] => 20220307083
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
[patent_app_type] => utility
[patent_app_number] => 17/670937
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49410
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17670937
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/670937 | ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT | Feb 13, 2022 | Abandoned |
Array
(
[id] => 17930220
[patent_doc_number] => 20220325345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => Methods and Compositions for Assessing Patients with Preeclampsia-Related Conditions Using MicroRNA
[patent_app_type] => utility
[patent_app_number] => 17/592818
[patent_app_country] => US
[patent_app_date] => 2022-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12034
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17592818
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/592818 | Methods and compositions for assessing patients with preeclampsia-related conditions using MicroRNA | Feb 3, 2022 | Issued |